Apontis Pharma AG - Asset Resilience Ratio
Apontis Pharma AG (APPH) has an Asset Resilience Ratio of -1.20% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Apontis Pharma AG debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2023)
This chart shows how Apontis Pharma AG's Asset Resilience Ratio has changed over time. See shareholders equity of Apontis Pharma AG for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Apontis Pharma AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Apontis Pharma AG (APPH) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €-643.20K | -1.2% |
| Total Liquid Assets | €-643.20K | -1.20% |
Asset Resilience Insights
- Limited Liquidity: Apontis Pharma AG maintains only -1.20% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Apontis Pharma AG Industry Peers by Asset Resilience Ratio
Compare Apontis Pharma AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Apontis Pharma AG (2019–2023)
The table below shows the annual Asset Resilience Ratio data for Apontis Pharma AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.52% | €-301.15K ≈ $-352.08K |
€57.46 Million ≈ $67.18 Million |
+0.30pp |
| 2022-12-31 | -0.82% | €-490.42K ≈ $-573.36K |
€59.85 Million ≈ $69.97 Million |
+0.17pp |
| 2021-12-31 | -0.99% | €-536.59K ≈ $-627.33K |
€54.13 Million ≈ $63.29 Million |
-3.14pp |
| 2020-12-31 | 2.15% | €638.66K ≈ $746.66K |
€29.69 Million ≈ $34.71 Million |
+0.22pp |
| 2019-12-31 | 1.93% | €590.66K ≈ $690.54K |
€30.59 Million ≈ $35.76 Million |
-- |
About Apontis Pharma AG
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, dylipidemia, secondary prophylaxis, and asthma, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. Apont… Read more